Skip to search formSkip to main contentSkip to account menu

OGX-011

Known as: ISIS 112989 
A mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. OGX-011 inhibits testosterone-repressed prostate message-2 (TRPM-2… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Thionucleotidesclusterin antisense oligonucleotide

Narrower (1)

custirsen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
MP24-05 TARGETING THE VAV3 ONCOGENE ENHANCES DOCETAXEL-INDUCED APOPTOSIS THROUGH THE INHIBITION OF ANDROGEN RECEPTOR PHOSPHORYLATION IN LNCAP PROSTATE CANCER CELLS UNDER CHRONIC HYPOXIA IN VITRO AND…
2011
2011
An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model.
4502 Background: Experimental evidence strongly implicate the AR and intra-tumoral androgen synthesis in promoting tumor cell… 
2011
2011
SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
TPS180 Background: Custirsen (OGX-011) is a second generation antisense oligonucleotide (ASO) with a prolonged tissue half-life… 
2007
2007
A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)
5069 Background: Clusterin, a cytoprotective chaperone protein that promotes cell survival, is associated with androgen… 
2007
2007
A phase I/II study of OGX-011 and a gemcitabine (GEM)/platinum regimen as first-line therapy in 85 patients with advanced non-small cell lung cancer
7596 Background: OGX-011 is a second-generation antisense oligonucleotide designed to knockdown expression of the cytoprotective… 
Review
2006
Review
2006
Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
  • G. Schmitz
  • Current opinion in molecular therapeutics (Print)
  • 2006
  • Corpus ID: 31467499
OncoGenex Technologies Inc in collaboration with Isis Pharmaceuticals Inc is developing OGX-011, an intravenously administered… 
Review
2006
Review
2006
The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer
This review summarise the authors’ recent experience in the development of antisense (AS) oligodeoxynucleotide (ODN) therapy that… 
2006
2006
A Phase I/II Study of Combination Neoadjuvant Hormone Therapy and Weekly OGX-011 Prior to Radical Prostatectomy in Patients with Localized Prostate Cancer
Abstract : The clusterin gene encodes a cytoprotective chaperone protein that promotes cell survival. Clusterin is expressed in a… 
2005
2005
A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154
3085 Background: The clusterin gene encodes a cytoprotective chaperone protein that promotes cell survival, is expressed in a… 
2004
2004
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy
3033 Background: The clusterin gene encodes a chaperone protein that promotes cell survival. Clusterin is expressed in a variety… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)